Primary non-Hodgkin's lymphoma of the nasopharynx: Prognostic factors and outcome of 113 Indian patients

Abstract

This single institutional study evaluated the prognostic factors and treatment outcome of 113 Indian patients with primary nasopharyngeal non-Hodgkin's lymphoma. At presentation, 28% had stage I and 62% had stage II disease. Treatment comprised of a combination of chemotherapy (CTh) and radiotherapy (RT) in the majority of the patients (76%). After a median follow-up of 56 months, the 5-year disease-free survival (DFS) and overall survival (OS) for the whole group were 55.8% and 57.9%, respectively. Multivariate analysis showed that; age > 30 years [hazard ratio (HR) = 6.59, 95% confidence interval (CI) = 2.59 – 16.7, P < 0.0001], WHO performance score ≥ 2 (HR = 2.34, 95% CI = 1.01 – 5.46, P = 0.050), T-cell lymphomas (HR = 2.81, 95% CI = 1.14 – 6.96, P < 0.001) and the presence of B symptoms (HR = 3.65, 95% CI = 1.77 – 7.53, P = 0.025), had a negative influence on survival. Patients treated with a combination of CTh and RT had a significantly better outcome than those treated with CTh alone (OS: 69%vs. 31%, P < 0.00001). HR for death in the CTh alone group was 3.73 (95% CI = 1.95 – 7.13). The CR (P = 0.01), DFS (P = 0.01) and OS (P = 0.03) rates were significantly better for patients receiving a RT dose of ≥4500 cGy. HR in the subgroup that received a RT dose of <4500 cGy was 2.51 (95% CI = 1.04 – 6.06). These results suggest that combined modality treatment, comprising of CTh and RT (with an RT dose of ≥4500 cGy), results in satisfactory outcome in patients with this rare neoplasm.

Keywords:

• Non-Hodgkin's lymphoma
• extranodal
• nasopharynx
• combined modality